Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs
暂无分享,去创建一个
A. Mangoni | D. Perra | A. Mathieu | M. Piga | A. Cauli | G. Erre | E. Chessa | A. Floris | M. M. Angioni | M. Congia | I. Cangemi
[1] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.
[2] A. Mangoni,et al. Aging Methotrexate and Vasculoprotection: Mechanistic Insights and Potential Therapeutic Applications in Old Age. , 2019, Current pharmaceutical design.
[3] A. Mangoni,et al. Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: A cross-sectional controlled study with real-time two-dimensional shear wave elastography. , 2019, European journal of internal medicine.
[4] J. Jacobs,et al. Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. , 2019, Joint, bone, spine : revue du rhumatisme.
[5] N. Wulffraat,et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis , 2018, PloS one.
[6] A. Barton,et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS) , 2018, Arthritis Research & Therapy.
[7] J. Jacobs,et al. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors , 2018, Annals of the rheumatic diseases.
[8] A. Mangoni,et al. Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence , 2017, Mediators of inflammation.
[9] I. McInnes,et al. Rheumatoid arthritis , 2016, The Lancet.
[10] P. V. van Riel,et al. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.
[11] R. Caporali,et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage , 2015, RMD Open.
[12] Se Jin Park,et al. Smoking and Rheumatoid Arthritis , 2014, International journal of molecular sciences.
[13] B. Combe,et al. Association of Tobacco Exposure and Reduction of Radiographic Progression in Early Rheumatoid Arthritis: Results From a French Multicenter Cohort , 2013, Arthritis care & research.
[14] H. Sayles,et al. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis , 2012, Arthritis care & research.
[15] F. Ibrahim,et al. Remission in Early Rheumatoid Arthritis: Predicting Treatment Response , 2012, The Journal of Rheumatology.
[16] S. Bergman,et al. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA , 2011, Scandinavian journal of rheumatology.
[17] R. Burgos-Vargas,et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study , 2011, Clinical Rheumatology.
[18] S. Saevarsdottir,et al. Predictors of response to methotrexate in early DMARD naïve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial , 2010, Annals of the rheumatic diseases.
[19] S. Wedrén,et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. , 2011, Arthritis and rheumatism.
[20] A. Silman,et al. UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .
[21] A. Silman,et al. Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .
[22] D. Sugiyama,et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies , 2009, Annals of the rheumatic diseases.
[23] M. Barclay,et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. , 2009, Arthritis and rheumatism.
[24] B. Bresnihan,et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study , 2009, Arthritis research & therapy.
[25] D. M. van der Heijde,et al. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.
[26] A. Nevill,et al. Cigarette smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[27] E. Karlson,et al. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. , 2006, The American journal of medicine.
[28] James M Robins,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[29] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.